AMAG Pharmaceuticals Inc (AMAG)
12.71
+0.24 +1.92%
NASDAQ
Mar 21, 20:00
Delayed 2m
USD
View All Key Stats
AMAG Key Stats
| Income Statement | |
| Revenue (TTM) | 502.97M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -1.92 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -65.76M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 67.41% |
| Profit Margin (Quarterly) | -25.28% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | Upgrade |
| Price and Valuation | |
| Market Cap | 441.20M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | 0.8691 |
| PE Ratio (TTM) | -- |
| Price to Book Value | 0.5909 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | Upgrade |
| Free Cash Flow (Quarterly) | -24.71M |
| Return on Equity (TTM) | Upgrade |
View All AMAG News
AMAG News
-
WireHeadlineTime (ET)
-
MT Newswires03/20 12:29
-
Globe Newswire03/20 08:00
-
Yahoo03/18 12:43
-
SA Breaking News03/15 08:53
-
Yahoo03/13 10:46
-
Yahoo03/11 10:35
-
Yahoo03/09 09:31
-
SA Breaking News03/08 12:57
-
Yahoo03/08 11:26
-
SA Breaking News03/08 11:06
View All Events
AMAG Events
| Date | Type | Description |
|---|---|---|
| 05/03/2019 08:00 EDT | Misc | AMAG Pharmaceuticals Inc First Quarter Earnings Conference Call in 2019 |
| 05/03/2019 | Earnings | AMAG Pharmaceuticals Inc First Quarter Earnings in 2019 Release |
| 03/01/2019 | Misc | AMAG Pharmaceuticals Inc Annual Report in 2018 |
| 02/07/2019 08:00 EST | Misc | AMAG Pharmaceuticals Inc Fourth Quarter Earnings Conference Call in 2018 |
| 02/07/2019 | Earnings | AMAG Pharmaceuticals Inc Fourth Quarter Earnings in 2018 Release |
| 11/01/2018 08:00 EDT | Misc | AMAG Pharmaceuticals Inc Third Quarter Earnings Conference Call in 2018 |
| 11/01/2018 | Earnings | AMAG Pharmaceuticals Inc Third Quarter Earnings Results in 2018 |
| 08/02/2018 08:00 EDT | Misc | AMAG Pharmaceuticals Inc Second Quarter Earnings Conference Call in 2018 |
| 08/02/2018 | Earnings | AMAG Pharmaceuticals Inc Second Quarter Earnings Results in 2018 |
| 06/07/2018 | Misc | AMAG Pharmaceuticals Inc Annual General Meeting in 2017 |
AMAG Fundamentals
Income Statement View Statement
AMAG Ratings
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
Advertisement
AMAG One Page Reports
- One Page Report Download
AMAG Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 12.71 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Edit
Profile
- URL: http://www.amagpharma.com
- Investor Relations URL: http://ir.amagpharma.com/phoenix.zhtml?c=61596&p=irol-irhome
- HQ State/Province: Massachusetts
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Value
- Next Earnings Release: May. 03, 2019
- Last Earnings Release: Feb. 07, 2019
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: AMAG Pharmaceuticals Inc primarily uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. Most of the revenues are generated through the sale of Feraheme and Makena which is a hydroxyprogesterone caproate injection.
AMAG Excel Add-In Codes
- Name: =YCI("AMAG","name")
- Description: =YCI("AMAG","description")
- Sector: =YCI("AMAG","sector")
- Industry: =YCI("AMAG","industry")
- Est. Current Fiscal Year End: =YCI("AMAG","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Other AMAG Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- AMAG Tweets Stocktwits
Advertisement
